Incannex Quarterly Loss Blows Past Estimates as Revenue Stays at Zero
IXHL is trading near its 52-week low of $1.955 (2.8% above the low).
Summary
Incannex reported a September-quarter adjusted loss of A$7.88 per share against a two-analyst consensus of a 49-cent loss — a wide miss, and the fourth straight quarter of missing estimates. Revenue was zero, as expected, and the reported net loss was A$2.75 million. The cash story is the offset: the 10-Q filed today shows $68.3M of cash with no new financing, so the loss is not a liquidity event. The stock is trading near its 52-week low of $1.955 after falling 39.0% this quarter and 81.6% this year, so the miss lands on an already-battered share price. The lone analyst rating is 'buy' with a median 12-month target of $18.61, roughly 89.4% above the last close of $1.98 — a gap that reflects clinical-stage optimism, not near-term earnings. Watch the DReAMzz Phase 2 IHL-42X sleep apnea readout as the next real driver; the December 17 annual meeting is a calendar item only.
At the time of this announcement, IXHL was trading at $2.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.2M. The 52-week trading range was $1.96 to $14.91. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.